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nother Step on the Road to
ailored Antiplatelet Therapy*
tephen D. Wiviott, MD,
essica L. Mega, MD, MPH
oston, Massachusetts
linical guidelines recommend dual antiplatelet therapy
fter an acute coronary syndrome (ACS) or percutaneous
oronary intervention (PCI). The antiplatelet agent clopi-
ogrel, a thienopyridine, has been the primary P2Y12
nhibitor used over the last decade and is a key component
f therapy for patients across the spectrum of coronary
rtery disease (1,2). Newer, more potent antiplatelet agents
uch as prasugrel (a third-generation thienopyridine) and
icagrelor (a nonthienopyridine P2Y12 inhibitor) both
chieve significantly higher levels of platelet inhibition and
ave demonstrated efficacy in reducing post-ACS ischemic
vents as compared with clopidogrel, with increased non-
oronary artery bypass graft bleeding (3,4). The adoption
nd use of these and other new agents will be influenced by
his balance of risk and benefit and likely by economic
ealities, as clopidogrel becomes generic. Thus, several
actors suggest that the use of clopidogrel will continue to be
idespread in the future.
See page 1630
There has been growing appreciation that not all patients
espond uniformly to standard doses of clopidogrel. This
ariable response is linked in large part to the underlying
etabolism; clopidogrel is a prodrug requiring biotransforma-
ion to form an active metabolite. Investigators have identified
number of factors that might interfere with the formation of
he active metabolite, including clinical characteristics, drug–
rug interactions, and polymorphisms in genes that encode
etabolic enzymes and transporters, particularly CYP2C19. In
Editorials published in the Journal of the American College of Cardiology reflect the
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merican College of Cardiology.
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straZeneca.esponse, the U.S. Food and Drug Administration (FDA)
ssued a boxed warning, indicating that individuals with 2
educed-function CYP2C19 alleles have a reduced response to
tandard doses of clopidogrel and that alternative treatment
trategies should be considered in such patients.
The FDA warning was influenced by several observations:
) individuals with particularCYP2C19 genetic variants tend to
orm less clopidogrel active metabolite and have less platelet
nhibition when receiving standard doses of clopidogrel; 2)
hese individuals have worse clinical outcomes, including an
ncreased risk of recurrent myocardial infarction and stent
hrombosis, particularly in the post-PCI setting; and 3) pa-
ients with high on-treatment platelet reactivity (HTPR),
egardless of genotype, are at higher risk for adverse clinical
utcomes. Clinicians have struggled with how to respond to
hese data, because there is limited information about whether
hanging medications or dosing of clopidogrel can overcome
he response variability and, even if it can, whether it will
itigate the excess clinical risks observed. In this issue of the
ournal, Bonello et al. (5) report the results of an important
roof-of-concept study examining one aspect of this contro-
ersy—whether intensifying clopidogrel therapy can overcome
TPR in the short term in patients with CYP2C19 reduced-
unction alleles.
Bonello et al. (5) tested whether serial loading doses of
lopidogrel could achieve vasodilator-stimulated phospho-
rotein (VASP) indexes 50% in individuals who had
ASP indexes 50% (the study definition of HTPR) after
n initial 600-mg loading dose; the results were evaluated
mong patients with 0, 1, and 2 reduced-function
YP2C19*2 alleles. A total of 411 patients with non–ST-
egment elevation ACS with planned PCI were enrolled. Of
hose, 277 patients carried no CYP2C19*2 alleles, of which
54 had HTPR after a 600-mg loading dose of clopidogrel;
23 patients carried one CYP2C19*2 allele, of which 97 had
TPR; and 11 patients carried two CYP2C19*2 alleles, of
hich 6 had HTPR. These data demonstrate that, even
efore consideration of the clinical intervention performed
n this study, the correlations between tests are imperfect—
ot all CYP2C19*2 carriers have HTPR and not all with
TPR are CYP2C19*2 carriers. Ultimately, the study dem-
nstrated that the intervention—serial loading of clopi-
ogrel (up to 2,400 mg given over 4 days)—could achieve
ASP indexes 50% in the vast majority of subjects, even
mong carriers of CYP2C19*2 alleles.
Therefore, this study illustrates a key principle: HTPR in
atients with genetic variants in CYP2C19 can be overcome
n many cases by altering the loading doses of clopidogrel.
he authors acknowledge, however, that this study was not
esigned to test whether this strategy is practical, clinically
fficacious, tolerable for many patients, or cost-effective (in
ome patients, as many as 3 additional days of therapy and
p to 1,800 mg of additional therapy were needed). Indeed,
n patients with ACS the greatest risk period is early, after
resentation, so serial loading doses of a medication to
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Tailored Antiplatelet Therapy November 9, 2010:1637–8chieve an effect over several days might leave a patient
ncompletely treated during the highest-risk period. In this
ra of the demonstrated benefits of early invasive therapy
nd concerns for hospital stay costs, such a strategy might
ot be widely adopted into practice.
Additionally, the study by Bonello et al. (5) tested
chieved platelet function and not clinical outcomes, and as
uch it was not designed to comment on the relative merits
f platelet function testing versus genotyping. It would be
ircular logic to conclude that platelet function testing is
etter than genotyping at identifying poor response to
lopidogrel when poor response status is being defined with
latelet function testing. Furthermore, only one-half of the
mall number of individuals in the study who carried 2
educed-function CYP2C19*2 alleles were found to have
TPR, an unexpected finding compared with previous
tudies. Other unanswered questions include: what would
ave been observed if additional platelet function tests were
erformed? And, how would these individuals with 1 or 2
educed-function CYP2C19*2 alleles fare with long-term
herapy? Additional studies will be instrumental in deter-
ining whether higher maintenance doses of clopidogrel in
he secondary prevention setting lead to an optimal anti-
latelet response among carriers of a reduced-function
YP2C19 allele.
To date, bothHTPR and theCYP2C19 genotype have been
ssociated with an increased risk of cardiovascular events,
ncluding stent thrombosis, in the setting of treatment with
tandard doses of clopidogrel (6–11). Importantly, these 2
etrics seem to offer independent information (12). Platelet
unction testing is attractive because it integrates many factors
t a specific time, including the clinical presentation (e.g., acute
s. chronic coronary artery disease) and the comorbidities of
he patient (e.g., diabetes). Genotyping, performed once,
dentifies a lifelong predisposition but might not account for all
actors influencing the response to clopidogrel. Yet, not every-
ne with a CYP2C19 reduced-function genetic variant (a
omplex rather than a Mendelian genetic trait) or abnormal
latelet function testing will experience an adverse cardiovas-
ular event in the setting of standard doses of clopidogrel. It
eems that in this situation it is a matter of shifting probabil-
ties, with the totality of the data suggesting that both the
YP2C19 genotype and HTPR are associated with an in-
reased risk of adverse cardiovascular outcomes with standard
oses of clopidogrel.
Thus, it is an exciting time for the cardiology community;
e are at a clinical crossroad and in the process of deter-
ining the future of how to best tailor therapy for our
atients. Prospective randomized clinical trials will be in-
trumental in determining the ultimate utility of personal-
zed antiplatelet therapy. Because these data are not cur-
ently available, the cardiology and regulatory communities
re grappling with how to best integrate platelet function
nd genetic data. There is precedent to use information,
uch as body weight or creatinine clearance that provides
nformation about anticipated drug levels and clearance, to
d
sdjust the dose of medications in the absence of dedicated
andomized trials. In a similar vein, the FDA has now
ighlighted that diagnostic testing can identify a cohort of
ndividuals who, on the whole, are less likely to respond
ptimally to standard doses of clopidogrel. Bonello et al. (5)
ave provided interesting information about altering the
oading dose of clopidogrel in patients with CYP2C19*2
enetic variants and HTPR, and thus the study takes
nother step on the path to a tailored and effective anti-
latelet therapy strategy.
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rancis Street, Boston, Massachusetts. E-mail: swiviott@
artners.org.
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